PMGC Holdings Subsidiary Finalizes Exclusive IP License for Animal Health Applications
ELAB is trading near its 52-week low of $1.52 (12% above the low) on light trading volume (0.2× avg).
Summary
PMGC Holdings Inc.'s subsidiary, Northstrive Biosciences Inc., entered into a definitive exclusive, royalty-bearing license agreement with Modulant Biosciences LLC for its intellectual property in non-human animal health.
Key Events · M&A and Partnerships · ELAB
-
Definitive License Agreement Executed
Northstrive Biosciences Inc., a wholly-owned subsidiary, finalized an exclusive, royalty-bearing, sublicensable license agreement with Modulant Biosciences LLC, formalizing a binding term sheet previously reported on May 16, 2025.
-
Focus on Non-Human Animal Health
The license grants Modulant rights to develop, manufacture, and commercialize Licensed Products solely in the field of non-human animal health, including feed additive applications, worldwide (excluding the Republic of Korea).
-
Revenue Sharing Model
Modulant will pay Northstrive Biosciences a percentage of all IP Revenue, with a higher rate until a certain aggregate threshold amount is met, then a lower rate thereafter. Specific percentages and the threshold amount are redacted.
-
Commitment to Commercialization
Modulant is obligated to use 'Commercially Reasonable Efforts' to develop and commercialize at least one Licensed Product in the specified field and territory.
Analysis · ELAB · Life Sciences
PMGC Holdings Inc.'s subsidiary, Northstrive Biosciences Inc., has finalized a definitive, exclusive, royalty-bearing license agreement with Modulant Biosciences LLC for its intellectual property related to myostatin and Activin-A for non-human animal health applications. This agreement formalizes the terms of a binding term sheet previously reported on May 16, 2025. For a life sciences company like PMGC Holdings, securing a definitive licensing agreement is a crucial step towards commercializing its intellectual property and establishing a long-term revenue stream, even if the specific financial terms (revenue share percentages and threshold amount) are redacted. This development follows a period of significant capital raises and an acquisition, indicating the company's active efforts to grow and monetize its assets.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 29.6% of the 2856 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELAB was trading at $1.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $1.52 to $185.22. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.